Medicosnext
Roche’s SARS-CoV-2 antibody test included in Moderna vaccine trials After receiving US FDA emergency use authorization for its Elecsys® Anti-SARS-CoV-2 antibody test on November 25, 2020, Roche has partnered with Moderna to utilize the test in the latter’s mRNA-1273 vaccine research trials. The antibody test measures the quantity of antibodies to the coronavirus spike protein through a blood sample. Roche’s fully-automated cobase analyzers, which have test throughput of up to 300 tests per hour, can provide results in about 18 minutes. The Moderna vaccine induces antibody response to the RBD (receptor binding domain) of the SARS-CoV-2 spike protein. Measuring the levels of anti-RBD SARS-CoV-2 antibodies will help to understand the correlation between protection from vaccination and antibody levels, and help establish vaccine efficacy.
Ref: Roche.com, December 9, 2020,
